Mpox: Diagnosis and Management for the Inpatient Dermatologist
Purpose of Review Mpox, though largely a self-limited disease, may have severe manifestations requiring hospitalization, particularly in immunocompromised individuals. This review highlights the history and epidemiology, clinical course, diagnostic pearls, and management of mpox in the context of inpatient dermatology. Recent Findings The 2022 outbreak had unique features in comparison to previous outbreaks and endemic mpox, including a predominance of anogenital lesions and an atypical progression of lesion morphologies. The frequency of concurrent STIs is as high as 76%- necessitating co-testing for HIV and other STIs. Intradermal administration of the live, nonreplicating vaccine (Jynneos) requires 1/$ 5^{th} $ of the standard dose, shows similar immunogenicity, and provides increased vaccination reach. Summary Mpox may require hospitalization in cases of severe disease, uncontrolled pain, or with other cutaneous complications. The inpatient dermatologist plays an important role diagnosis of mpox and should recognize the variability in morphologic presentation and need for STI and HIV co-testing..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
Current dermatology reports - 12(2023), 4 vom: Dez., Seite 180-192 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Strahan, Alexis G. [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| Themen: |
Hospitalization |
|---|
| Anmerkungen: |
© The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. |
|---|
| doi: |
10.1007/s13671-023-00411-x |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR054283930 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR054283930 | ||
| 003 | DE-627 | ||
| 005 | 20240106064643.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240106s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s13671-023-00411-x |2 doi | |
| 035 | |a (DE-627)SPR054283930 | ||
| 035 | |a (SPR)s13671-023-00411-x-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Strahan, Alexis G. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Mpox: Diagnosis and Management for the Inpatient Dermatologist |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. | ||
| 520 | |a Purpose of Review Mpox, though largely a self-limited disease, may have severe manifestations requiring hospitalization, particularly in immunocompromised individuals. This review highlights the history and epidemiology, clinical course, diagnostic pearls, and management of mpox in the context of inpatient dermatology. Recent Findings The 2022 outbreak had unique features in comparison to previous outbreaks and endemic mpox, including a predominance of anogenital lesions and an atypical progression of lesion morphologies. The frequency of concurrent STIs is as high as 76%- necessitating co-testing for HIV and other STIs. Intradermal administration of the live, nonreplicating vaccine (Jynneos) requires 1/$ 5^{th} $ of the standard dose, shows similar immunogenicity, and provides increased vaccination reach. Summary Mpox may require hospitalization in cases of severe disease, uncontrolled pain, or with other cutaneous complications. The inpatient dermatologist plays an important role diagnosis of mpox and should recognize the variability in morphologic presentation and need for STI and HIV co-testing. | ||
| 650 | 4 | |a Mpox |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Monkeypox |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Virus |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Outbreak |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Inpatient dermatology |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Hospitalization |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Collier, Sigrid |4 aut | |
| 700 | 1 | |a Trinidad, John |4 aut | |
| 700 | 1 | |a Harp, Joanna |4 aut | |
| 700 | 1 | |a Freeman, Esther E. |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current dermatology reports |d New York, NY : Springer, 2012 |g 12(2023), 4 vom: Dez., Seite 180-192 |w (DE-627)SPR032151217 |w (DE-600)2660493-0 |x 2162-4933 |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2023 |g number:4 |g month:12 |g pages:180-192 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s13671-023-00411-x |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2023 |e 4 |c 12 |h 180-192 | ||